Positive opinion moves eribulin closer to approval in Japan
This article was originally published in Scrip
Eisai's novel anticancer agent Halaven (eribulin mesylate) has received a positive approval recommendation in Japan for use in breast cancer, taking it a step closer to launch in what will become an important market.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.